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Abstract
● This study evaluated the clinical outcomes in keratoconus 
corneas following accelerated transepithelial corneal 
collagen cross-linking (CXL) (Avedro KXL® system, Waltham, 
MA, USA) over one year of follow-up. The mean depth 
of the demarcation line measured by optical coherence 
tomography (OCT) was 205.19 µm. One month after 
surgery, a non-statistically significant change was noted 
in sphere (P=0.18) and in spherical equivalent (P=0.17), 
whereas a significant improvement was observed in 
corrected distance visual acuity (P=0.04). A significant 
change was observed in topographic astigmatism (P=0.03) 
and posterior corneal a sphericity (P=0.04). Accelerated 
transepithelial CXL may be a useful technique for the 
management of progressive keratoconus.
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INTRODUCTION
Corneal collagen cross-linking (CXL) is a method aimed at increasing the number of bonds between the collagen 
chains of the corneal stroma, thus inducing a change in the 
mechanical properties of the cornea[1]. This technique has been 
shown to be effective in the field of corneal ectasia, preventing 
its progression and even regularising the corneal surface in 
these cases[1-6]. The need for epithelial debridement of the 
cornea to obtain a sufficient degree of riboflavin penetration 
and consequently a greater cross-linking effect was one of the 
main initial drawbacks of the CXL technique, as it prolonged 
the recovery and increased postoperative discomfort[7]. For 
this reason, new CXL protocols are being developed in order 
to avoid having to debride the corneal epithelium, such as 
transepithelial CXL[7].
SUBJECTS AND METHODS
This prospective, randomised study evaluated a total of 19 
keratoconus eyes of 12 patients aged between 26 and 69y 
undergoing accelerated transepithelial CXL. All patients 
belonged to the Corneal and Anterior Segment Unit of the 
Ophthalmology Department (OFTALMAR), Vithas Medimar 
International Hospital (Alicante, Spain). The study inclusion 
criterion was the presence of progressive keratoconus: 
central topographic steepening of more than 1 diopters (D) 
with refractive change of more than 0.50 D in the last 6mo. 
The standard criterion for diagnosing keratoconus was used: 
corneal topography showing an asymmetric bow-tie pattern 
with or without inclined axes and at least one keratoconic 
sign on slit-lamp examination, such as stromal thinning, conic 
protrusion of the cornea atthe apex, Fleischer's ring, Vogt's 
striae or anterior stromal scarring. The exclusion criteria were 
previous eye surgery and the presence of any type of active 
eye disease. All patients were properly informed about their 
inclusion and signed an informed consent form. The study 
complied with the principles of the Declaration of Helsinki, 
and was approved by the Hospital Ethics Committee.
A complete ophthalmological examination was carried out 
preoperatively, which included measurement of manifest 
refraction, uncorrected distance visual acuity (UDVA) and 
corrected distance visual acuity (CDVA), Goldmann applanation 
tonometry, anterior segment slit-lamp examination, corneal 
topography and aberrometry (Sirius, CSO, Florence, Italy), 
optical biometry and eye fundus examination. Postoperatively, 
patients were reviewed 1d, 1, 6 and 12mo post-surgery. The 
day after the surgery, a biomicrosopic examination of the 
cornea was carried out, as well as an analysis of the cornea 
by optical coherence tomography (OCT; 3D-1000 system, 
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Topcon), measuring the depth of the area of highest reflectance 
(corneal demarcation line). The same examination protocol as 
in the preoperative period was used at 1, 6 and 12mo.
All operations were performed by the same expert surgeon 
(Artola A) under topical anaesthesia, using the Avedro KXL 
cross-linking system (Waltham, MA, USA). The procedure 
began with the instillation, every 90s for a total of 4min, of 
dextran-free hypo-osmolar riboflavin drops containing agents 
to improve the epithelial permeability, including benzalkonium 
chloride (Paracel, Avedro, Waltham, MA, USA). A benzalkonium 
chloride-free 0.25% riboflavin solution (VibeXXtra, Avedro, 
Waltham, MA, USA) was then instilled at the same rate for 
6min. Once these steps had been completed, ultraviolet radiati-
on was applied for 2min and 40s, using a pulsed light protocol 
(2s ON /1s OFF). The total energy irradiated was 7.2 J/cm2 and 
the ultraviolet power was 45 mW/cm2. After irradiation, the 
cornea was rinsed with balanced saline solution.
RESULTS AND DISCUSSION
One month after surgery, a non-statistically significant change 
was noted in sphere (P=0.18) and in spherical equivalent 
(P=0.17), with no associated significant changes in cylinder 
(P=0.65) or logMAR UDVA (P=0.26). Likewise, a slight but 
statistically significant difference was observed in logMAR 
CDVA at 1mo postoperatively (P=0.04). There were no 
significant changes in either visual acuity or refraction between 
1 and 12mo (P≥0.40) (Table 1).
Table 1 shows also a summary of the corneal topography 
changes observed post-operatively. Only a statistically significant 
changed with surgery was observed in the magnitude of the 
astigmatism of the posterior surface (P=0.03) and in posterior 
corneal asphericity (P=0.04). Regarding corneal aberrations, 
no significant changes were noted at 1mo post-surgery (P≥0.09) 
or in the remaining follow-up (P≥0.08; Table 2).
Finally, the mean depth of the demarcation line measured by 
OCT varied between 153 and 230 µm, with a mean value of 
205.19 µm (SD: 19.75; median: 205 µm).
In this study, we observed that the accelerated transepithelial 
CXL technique induces variable changes in the spherical 
defect and spherical equivalent of the patient. Thus, changes 
in the mechanical properties of the cornea induced by cross-
linking seem to produce a change in the optical properties of 
the cornea, eventually affecting the refractive level. This is 
consistent with the findings reported in other series evaluating 
the results of transepithelial CXL, either by iontophoresis or 
accelerated[8-12]. Similarly, in line with all previous studies on 
transepithelial CXL[8-12], a significant improvement in CDVA 
was observed after surgery that remained throughout the entire 
12mo follow-up period.
As regards topographic changes after CXL, central flattening 
of the anterior corneal surface was observed in our series, 
which did not reach statistical significance. No significant 
changes were noted either in the curvature of the posterior 
corneal surface during the 12-month follow-up period, or in 
the asphericity of the anterior surface. A statistically significant 
change towards more negative asphericity values was observed 
for the posterior corneal surface. Lesniak and Hersh[10] found 
Table 1 Summary of the visual, refractive, corneal topographic and pachymetric outcomes in the analyzed sample
Parameters
Preop. 1mo 12mo P (12mo vs 
preop.)Mean (SD) Median (range) Mean (SD) Median (range) Mean (SD) Median (range)
 UDVA (logMAR) 0.51 (0.45) 0.40 (0.05 to 1.30) 0.38 (0.39) 0.30 (0.05 to 1.30) 0.29 (0.28) 0.30 (0.00 to 0.70) 0.89
CDVA (logMAR) 0.30 (0.25) 0.26 (0.00 to 0.80) 0.19 (0.25) 0.15 (0.00 to 1.00) 0.23 (0.31) 0.15 (0.00 to 1.00) 0.30
Sphere (D) +0.38 (1.77) 0.00 (-2.50 to +3.25) +1.03 (1.83) 0.00 (-1.50 to +4.00) -0.05 (1.76) -0.25 (-2.50 to +3.50) 0.32
Cylinder (D) -2.76 (1.96) -2.00 (-6.00 to 0.00) -3.18 (1.99) -4.00 (-6.00 to 0.00) -2.70 (2.17) -2.50 (-6.00 to 0.00) 0.24
Spherical equivalent (D) -1.03 (1.28) -0.94 (-3.50 to +1.00) -0.56 (1.29) -0.38 (-2.63 to +1.75) -1.40 (1.85) -1.25 (-5.50 to +1.50) 0.25
KMa (D) 48.48 (3.40) 47.96 (44.27 to 53.70) 49.75 (4.95) 47.54 (45.06 to 59.90) 47.33 (2.18) 47.35 (44.88 to 51.19) 0.32
ACA (D) 3.70 (1.00) 3.97 (1.76 to 5.10) 4.50 (1.72) 4.46 (1.26 to 6.80) 4.06 (1.39) 3.82 (2.36 to 6.36) 0.58
KMp (D) 7.07 (0.91) 7.05 (4.96 to 8.48) 7.57 (1.09) 7.11 (6.09 to 9.01) 6.87 (0.92) 6.75 (5.89 to 8.93) 0.82
PCA (D) 1.14 (0.79) 1.02 (0.23 to 3.94) 0.98 (0.45) 0.94 (0.22 to 1.85) 1.81 (1.03) 1.53 (0.94 to 4.11) 0.03
Qa -0.75 (0.42) -0.67 (-1.92 to -0.11) -0.94 (0.40) -0.84 (-1.58 to -0.43) -0.70 (0.28) -0.65 (-1.30 to -0.30) 0.70
Qp -0.71 (0.55) -0.62 (-1.90 to -0.09) -1.08 (0.64) -1.01 (-1.96 to -0.16) -0.91 (0.48) -0.83 (-1.95 to -0.45) 0.04
CCT (µm) 476.61 (42.17) 489.50 (399 to 541) 474.08 (50.82) 464.00 (418 to 557) 491.38 (25.37) 504.00 (443 to 514) 0.28
MCT (µm) 452.83 (46.10) 460.00 (385 to 538) 453.42 (56.98) 437.50 (384 to 546) 473.25 (32.63) 485.50 (409 to 511) 0.27
X position MCT (mm) -0.04 (0.63) -0.04 (-0.89 to 0.71) 0.07 (0.70) 0.09 (-0.72 to 1.29) -0.07 (0.54) -0.07 (-0.77 to 0.61) 0.25
Y position MCT (mm) -0.76 (0.35) -0.78 (-1.26 to -0.13) -0.47 (0.56) -0.53 (-1.24 to 1.03) -0.61 (0.58) -0.72 (-1.36 to 0.63) 0.37
Corneal volume (mm3) 55.65 (4.66) 55.00 (47.80 to 62.90) 56.33 (4.59) 55.30 (49.50 to 66.80) 55.65 (2.41) 55.85 (51.80 to 58.80) 0.10
SD: Standard deviation; D: Diopters; UDVA: Uncorrected distance visual acuity; CDVA: Corrected distance visual acuity; KMa: Anterior mean keratometry; 
ACA: Anterior corneal astigmatism in the 3-mm central area; KMp: Posterior mean keratometry; PCA: Posterior corneal astigmatism in the 3-mm central 
area; Qa: Asphericity of the anterior corneal surface in the central 8-mm area; Qp: Asphericity of the posterior corneal surface in the central 8-mm area; CCT: 
Central corneal thickness; MCM: Minimal corneal thickness.
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a mean reduction of 0.9 D in the maximum keratometry in a 
prospective study that evaluated the results of a similar CXL 
technique than that used in our study over a 6mo period. It 
should be borne in mind that this study included keratoconus 
cases that were more advanced than in our series, so the mean 
keratometry was higher. However, a statistically significant 
change was observed in the magnitude of the astigmatism 
of the posterior surface between 1 and 12mo after surgery, 
causing an increase in this value. This could be indicative of 
more long-term changes in the corneal structure after CXL. 
The different degrees of riboflavin penetration from one eye to 
another may also have played a crucial role in the variability of 
the CXL effect. More complex studies are therefore required 
that characterise the in vivo changes at the biomechanical level 
of the cornea structure, as have already been studied ex vivo[13]. 
With respect to corneal aberrations, as with the topographic 
parameters, there was wide inter-patient variability, with no 
statistically significant changes.
The central and minimum pachymetry underwent changes, but 
they did not reach statistical significance. A non-significant 
trend towards a reduction in pachymetric values was observed 
1mo after the surgery, with thickening at 12mo. Similar trends 
were reported by Nawaz et al[14] comparing patients with 
keratoconus undergoing conventional or transepithelial CXL. 
Finally, the corneal demarcation line measured by OCT had a 
mean depth of 202.72 µm, which is consistent with the degree 
of riboflavin penetration measured in experimental studies that 
have evaluated the effect of transepithelial CXL[15].
In summary, accelerated transepithelial CXL could be a 
potentially useful technique for the management of progressive 
corneal ectasia, as it can maintain the topographic and 
aberrometric profile of the cornea without significant changes 
for a period of 12mo after the procedure. Future studies are 
warranted that show the corneal biomechanical changes that 
occur in-vivo with the use of this technique.
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